NDATOPICALCREAM
Approved
Jun 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
6/8 — Strong
BETAMETHASONE DIPROPIONATE (betamethasone dipropionate) by Sandoz is clinical pharmacology: topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. Approved for psoriasis, atopic dermatitis. First approved in 1984.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Betamethasone dipropionate is a potent topical corticosteroid cream approved since 1984 for treating mild to moderate plaque psoriasis in adults. It works by suppressing inflammatory immune responses and reducing itching through glucocorticoid receptor activation and modulation of inflammatory cell mediators. The drug is absorbed through intact and inflamed skin, metabolized hepatically, and excreted renally.
$5MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D utilization signals a mature, commoditized asset with likely consolidation of support functions.
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications (2)
Worked on BETAMETHASONE DIPROPIONATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.